Summary of the published data and standardized mean differences (SMDs; Hedge’s g) of DLQI measured prior to and after the commencement of infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib plaque psoriasis patients.
收藏NIAID Data Ecosystem2026-03-12 收录
数据链接：
官方服务：
资源简介：
Summary of the published data and standardized mean differences (SMDs; Hedge’s g) of DLQI measured prior to and after the commencement of infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib plaque psoriasis patients.
创建时间：
2020-12-03
